Filter your results
- 2
- 1
- 3
- 3
- 1
- 1
- 1
- 3
- 3
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialHaematologica, 2015, 100 (6), pp.780 - 785. ⟨10.3324/haematol.2014.114884⟩
Journal articles
inserm-01820455v1
|
||
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupBlood, 2014, 124 (8), pp.1312 - 1319. ⟨10.1182/blood-2014-01-549212⟩
Journal articles
hal-01688071v1
|
|||
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialEuropean Journal of Haematology, 2021, 107 (1), pp.111-121. ⟨10.1111/ejh.13626⟩
Journal articles
hal-03604930v1
|